Shreya Life Sciences Launches Oral-Recosulin in India

newswatch's picture
Posted 2 December 2008 - 12:39pm by newswatch
newswatch

Shreya Life Sciences announced the launch of recombinant DNA human insulin buccal spray under the brand name of Oral-Recosulin.  Ultra Rapid Prandial Glucose Regulator is a buccal insulin spray for the treatment of Type I and Type II diabetes that is based on the technology developed by the company's US collaborator Generex Biotechnology. Through its breakthrough "RapidMist" technology in insulin delivery, Oral Recosulin provides freedom from limitations of conventional insulin therapy / devices. The new technology delivers insulin through Buccal Mucosa directly to the Vascular System. It is observed that needle phobia is a primary reason, which at times prevents the patient from taking insulin therapy although required. Oral-Recosulin is an alternative available for those diabetics who have an acute injection phobia.

A study by the World Health Organization (WHO) estimated the number of diabetic individuals in India to rise from19.4 mn in 1995 to 57.2 mn by the year 2025 making India  home to the largest diabetic population in the world. The Indian Diabetic Market is estimated to be around 1722.7 Cr with a growth rate of 20.6%  as per the ORG IMS. Human Insulin market is Rs 517.9 Cr with a growth rate of 23.9% while the oral anti diabetic market is Rs.1204.7 Cr & is growing at the rate of 19.2%.  WHO's Burden of Disease report states that diabetes is going to grow by 40% in developed countries, but by 170% in developing countries. A study by IDF has shown that by 2030, the number of rural people suffering from diabetes will equal those in urban areas.

Terms & Conditions